Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada

British Journal of Haematology
Lee MozessohnRena Buckstein

Abstract

The outcome of myelodysplastic syndrome (MDS) patients with uniformly higher-risk disease treated with azacitidine (AZA) in the 'real-world' remains largely unknown. We evaluated 1101 consecutive higher-risk MDS patients (International Prognostic Scoring System intermediate-2/high) and low-blast count acute myeloid leukaemia (AML; 21-30% blasts) patients treated in Ontario, Canada. By dosing schedule, 24·7% received AZA for seven consecutive days, 12·4% for six consecutive days and 62·9% by 5-2-2. Overall, median number of cycles was 6 (range 1-67) and 8 (range 6-14) when restricted to the 692 (63%) patients who received at least 4 cycles. The actuarial median survival was 11·6 months [95% confidence interval (CI) 10·7-12·4) for the entire cohort and 18·0 months (landmark analysis; 95% CI 16·6-19·1 months) for those receiving at least 4 cycles. There was no difference in overall survival (OS) between the 3 dosing schedules (P = 0·87). In our large 'real-world' evaluation of AZA in higher-risk MDS/low-blast count AML, we demonstrated a lower than expected OS. Reassuringly, survival did not differ by dosing schedules. The OS was higher in the 2/3 of patients who received at least 4 cycles of treatment, reinforcing the necessity o...Continue Reading

References

Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanUNKNOWN Cancer and Leukemia Group B
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger M LyonsC L Beach
Jul 2, 2010·Cancer Treatment Reviews·Rena BucksteinUNKNOWN Canadian Consortium on Evidence-based Care in MDS
Jul 1, 2011·The New England Journal of Medicine·Rafael BejarBenjamin L Ebert
Aug 21, 2013·Blood Reviews·Amer M ZeidanSteven D Gore
Sep 14, 2013·Blood·Elli PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Mar 15, 2014·Journal of the National Cancer Institute·Joseph M UngerDawn L Hershman
Mar 15, 2014·Journal of the National Cancer Institute·Archie Bleyer

❮ Previous
Next ❯

Citations

Dec 10, 2019·Leukemia & Lymphoma·Namrata S ChandhokThomas Prebet
Sep 13, 2019·Expert Opinion on Investigational Drugs·Georgina S Daher-ReyesKaren W L Yee
Dec 7, 2019·Hematology·Guillermo F Sanz
Mar 9, 2020·Chinese Journal of Integrative Medicine·Jing MingXiao-Mei Hu
Nov 23, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P FenauxUNKNOWN ESMO Guidelines Committee
May 20, 2021·American Society of Clinical Oncology Educational Book·Robert P HasserjianMrinal M Patnaik
Jun 29, 2021·British Journal of Haematology·Sally B KillickDavid Bowen

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.